Adult; Aged; Aged, 80 and over; Anti-HIV Agents/pharmacology; Belgium/epidemiology; Drug Resistance, Viral/genetics; Female; Genotype; HIV Infections/epidemiology/physiopathology/transmission/virology; HIV Protease/genetics; HIV Reverse Transcriptase/genetics; HIV-1/drug effects/genetics/isolation & purification; Humans; Male; Middle Aged; Molecular Sequence Data; Prospective Studies; Questionnaires; RNA, Viral/blood/genetics/isolation & purification; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA
Abstract :
[en] This study is the first prospective study to assess the prevalence, epidemiology, and risk factors of HIV-1 drug resistance in newly diagnosed HIV-infected patients in Belgium. In January 2003 it was initiated as part of the pan-European SPREAD program, and continued thereafter for four inclusion rounds until December 2006. Epidemiological, clinical, and behavioral data were collected using a standardized questionnaire and genotypic resistance testing was done on a sample taken within 6 months of diagnosis. Two hundred and eighty-five patients were included. The overall prevalence of transmitted HIV-1 drug resistance in Belgium was 9.5% (27/285, 95% CI: 6.6-13.4). Being infected in Belgium, which largely coincided with harboring a subtype B virus, was found to be significantly associated with transmission of drug resistance. The relatively high rate of baseline resistance might jeopardize the success of first line treatment as more than 1 out of 10 (30/285, 10.5%) viruses did not score as fully susceptible to one of the recommended first-line regimens, i.e., zidovudine, lamivudine, and efavirenz. Our results support the implementation of genotypic resistance testing as a standard of care in all treatment-naive patients in Belgium.
Disciplines :
Immunology & infectious disease
Author, co-author :
Vercauteren, Jurgen; Katholieke Universiteit Leuven - KUL > Rega Institute for Medical Research and University Hospitals
Derdelinckx, Inge; Katholieke Universiteit Leuven - KUL > Rega Institute for Medical Research and University Hospitals
Sasse, Andre; Scientific Institute of Public Health, Brussels, Belgium.
Bogaert, Marleen; Universitair Ziekenhuis Gent - UZ
Ceunen, Helga; Katholieke Universiteit Leuven - KUL > Rega Institute for Medical Research and University Hospitals
De Roo, Ann
De Wit, Stephane
Deforche, Koen
Echahidi, Fedoua
Fransen, Katrien
Goffard, Jean-Christophe
Goubau, Patrick
Goudeseune, Elodie
Yombi, Jean-Cyr
Lacor, Patrick
Liesnard, Corinne
Moutschen, Michel ; Université de Liège - ULiège > Département des sciences cliniques > Immunopathologie - Transplantation
Geretti AM: Epidemiology of antiretroviral drug resistance in drug-naive persons. Curr Opin Infect Dis 2007;20:22-32.
Lama JR, Sanchez J, Suarez L, et al.: Linking HIV and antiretroviral drug resistance surveillance in Peru: A model for a third-generation HIV sentinel surveillance. J Acquir Immune Defic Syndr 2006;42:501-505.
Shet A, Berry L, Mohri H, et al.: Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: A decade of experience. J Acquir Immune Defic Syndr 2006;41:439-446.
Wensing AM and Vercauteren J: Transmission of drug resistant HIV in Europe remains limited to single classes. AIDS 2008, in press.
Shafer RW, Rhee SY, Pillay D, et al.: HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007;21:215-223.
Vercauteren J and Vandamme AM: Algorithms for the interpretation of HIV-1 genotypic drug resistance information. Antiviral Res 2006;71:335-342.
Ghosn J, Pellegrin I, Goujard C, et al.: HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 2006;20:159-170.
Brenner BG, Roger M, Routy JP, et al.: High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis 2007;195:951-959.
Van Laethem K, Schrooten Y, Lemey P, et al.: Consecutive transmission of dual-class resistant HIV-1 in untreated patients. 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, February 5-8, 2006.
Vandamme AM, Sonnerborg A, Ait-Khaled M, et al.: Updated European recommendations for the clinical use of HIV drug resistance testing. Antiviral Ther 2004;9:829-848.
Sax PE, Islam R, Walensky RP, et al.: Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis 2005;41:1316-1323.
Van Vaerenbergh K, Debaisieux L, De Cabooter N, et al.: Prevalence of genotypic resistance among antiretroviral drug-naive HIV-1-infected patients in Belgium. Antiviral Ther 2001;6:63-70.
Derdelinckx I, Van Laethem K, Maes B, et al.: Current levels of drug resistance among therapy-naive HIV-infected patients have significant impact on treatment response. J Acquir Immune Defic Syndr 2004;37:1664-1666.
Derdelinckx I, Van Laethem K, De Roo A, et al.: Prospective collection of data on the prevalence of transmitted resistance in newly diagnosed HIV-infected individuals in Belgium in 2003. Second European HIV Drug Resistance Workshop, Rome, 11-13 March 2004.
Weinstein MC, Goldie SJ, Losina E, et al.: Use of genotypic resistance testing to guide HIV therapy: Clinical impact and cost-effectiveness. Ann Intern Med 2001;134:440-450.
Maes B, Schrooten Y, Snoeck J, et al.: Performance of ViroSeq HIV-1 genotyping system in routine practice at a Belgian clinical laboratory. J Virol Methods 2004;119:45-49.
Van Laethem K, De Luca A, Antinori A, Cingolani A, Perna CF, and Vandamme AM: A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients. Antiviral Ther 2002;7:123-129.
de Oliveira T, Deforche K, Cassol S, et al.: An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 2005;21:3797-3800.
Palma AC, Araujo F, Duque V, Borges F, Paixao MT, and Camacho R: Molecular epidemiology and prevalence of drug resistance-associated mutations in newly diagnosed HIV-1 patients in Portugal. Infect Genet Evol 2007;7:391-398.
Paraskevis D, Magiorkinis E, Katsoulidou A, et al.: Prevalence of resistance-associated mutations in newly diagnosed HIV-1 patients in Greece. Virus Res 2005;112:115-122.
Little SJ, Holte S, Routy JP, et al.: Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002;347:385-394.
Leigh Brown AJ, Frost SD, Mathews WC, et al.: Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis 2003;187:683-686.
Garcia-Lerma JG, Nidtha S, Blumoff K, Weinstock H, and Heneine W: Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc Natl Acad Sci USA 2001;98:13907-13912.
Hammer SM, Saag MS, Schechter M, et al.: Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006;296:827-843.
Van Laethem K, Van Vaerenbergh K, Schmit JC, et al.: Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations. J Acquir Immune Defic Syndr 1999;22:107-118.
Van Laethem K, Schrooten Y, Lemey P, et al.: Consecutive transmission of dual-class resistant HIV-1 in untreated patients. Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, February 5-8, 2006.
Masquelier B, Bhaskaran K, Pillay D, et al.: Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: Data from seroconverters in the CASCADE collaboration from 1987 to 2003. J Acquir Immune Defic Syndr 2005;40:505-511.
UK Collaborative Group on HIV Drug Resistance: Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom. AIDS 2007;21:1035-1039.
Saul J, Erwin J, Sabin CA, Kulasegaram R, and Peters BS: The relationships between ethnicity, sex, risk group, and virus load in human immunodeficiency virus type 1 antiretroviral-naive patients. J Infect Dis 2001;183:1518-1521.
Smith PR, Sarner L, Murphy M, et al.: Ethnicity and discordance in plasma HIV-1 RNA viral load and CD4+ lymphocyte count in a cohort of HIV-1-infected individuals. J Clin Virol 2003;26:101-107.